Strata Wealth Advisors LLC Buys 26 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

Strata Wealth Advisors LLC raised its position in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 6.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The fund owned 422 shares of the medical research company’s stock after buying an additional 26 shares during the quarter. Strata Wealth Advisors LLC’s holdings in Thermo Fisher Scientific were worth $220,000 at the end of the most recent reporting period.

A number of other institutional investors have also modified their holdings of the company. Lyell Wealth Management LP lifted its holdings in shares of Thermo Fisher Scientific by 1.4% during the 4th quarter. Lyell Wealth Management LP now owns 29,768 shares of the medical research company’s stock valued at $15,486,000 after purchasing an additional 408 shares during the last quarter. Semus Wealth Partners LLC raised its stake in Thermo Fisher Scientific by 4.0% in the fourth quarter. Semus Wealth Partners LLC now owns 471 shares of the medical research company’s stock valued at $245,000 after buying an additional 18 shares during the last quarter. Kentucky Retirement Systems Insurance Trust Fund boosted its holdings in Thermo Fisher Scientific by 13.1% in the fourth quarter. Kentucky Retirement Systems Insurance Trust Fund now owns 12,797 shares of the medical research company’s stock worth $6,657,000 after acquiring an additional 1,487 shares in the last quarter. Proactive Wealth Strategies LLC increased its holdings in shares of Thermo Fisher Scientific by 2.7% during the fourth quarter. Proactive Wealth Strategies LLC now owns 753 shares of the medical research company’s stock valued at $392,000 after acquiring an additional 20 shares in the last quarter. Finally, Ramsay Stattman Vela & Price Inc. raised its position in shares of Thermo Fisher Scientific by 1.9% in the 4th quarter. Ramsay Stattman Vela & Price Inc. now owns 15,293 shares of the medical research company’s stock valued at $7,956,000 after purchasing an additional 281 shares during the last quarter. 89.23% of the stock is currently owned by institutional investors.

Insider Activity at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction on Monday, December 2nd. The stock was sold at an average price of $530.26, for a total value of $5,302,600.00. Following the completion of the sale, the chief executive officer now directly owns 111,192 shares in the company, valued at $58,960,669.92. This represents a 8.25 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, EVP Gianluca Pettiti sold 300 shares of Thermo Fisher Scientific stock in a transaction on Tuesday, February 4th. The stock was sold at an average price of $585.59, for a total value of $175,677.00. Following the transaction, the executive vice president now owns 16,363 shares in the company, valued at approximately $9,582,009.17. This represents a 1.80 % decrease in their position. The disclosure for this sale can be found here. In the last ninety days, insiders sold 20,125 shares of company stock valued at $11,231,699. 0.34% of the stock is owned by insiders.

Thermo Fisher Scientific Price Performance

Shares of NYSE TMO opened at $522.91 on Wednesday. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The firm has a market cap of $200.01 billion, a PE ratio of 31.63, a PEG ratio of 2.95 and a beta of 0.77. Thermo Fisher Scientific Inc. has a one year low of $493.30 and a one year high of $627.88. The firm has a fifty day moving average of $548.15 and a 200 day moving average of $568.62.

Thermo Fisher Scientific (NYSE:TMO) last released its quarterly earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share for the quarter, topping the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a net margin of 14.78% and a return on equity of 17.51%. As a group, research analysts predict that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific declared that its board has authorized a stock repurchase plan on Friday, November 15th that permits the company to repurchase $4.00 billion in outstanding shares. This repurchase authorization permits the medical research company to purchase up to 2% of its stock through open market purchases. Stock repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on TMO shares. Raymond James restated an “outperform” rating and set a $667.00 price target (up previously from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. UBS Group upped their target price on Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a “buy” rating in a research report on Friday, January 31st. Sanford C. Bernstein upgraded Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price target on the stock in a research note on Friday, January 10th. Robert W. Baird reduced their price objective on Thermo Fisher Scientific from $632.00 to $622.00 and set an “outperform” rating for the company in a research note on Thursday, October 24th. Finally, Wells Fargo & Company increased their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an “overweight” rating in a report on Friday, January 31st. Four equities research analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. According to data from MarketBeat.com, Thermo Fisher Scientific has a consensus rating of “Moderate Buy” and an average price target of $658.00.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.